<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Aging</journal-id>
<journal-title>Frontiers in Aging</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Aging</abbrev-journal-title>
<issn pub-type="epub">2673-6217</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1260053</article-id>
<article-id pub-id-type="doi">10.3389/fragi.2023.1260053</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Aging</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Two vicious circles associated with the aging of the immune system in the development of severe forms of COVID-19</article-title>
<alt-title alt-title-type="left-running-head">Vrbic and Milinkovic</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fragi.2023.1260053">10.3389/fragi.2023.1260053</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Vrbic</surname>
<given-names>Miodrag</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2379884/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Milinkovic</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Clinic for Infectious Diseases&#x2014;UCC Nis</institution>, <addr-line>Nis</addr-line>, <country>Serbia</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Chelsea and Westminster Foundation Trust and Imperial College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/367071/overview">Calogero Caruso</ext-link>, University of Palermo, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1938473/overview">Atefe Ghamar Talepoor</ext-link>, Shiraz University of Medical Sciences, Iran</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/381929/overview">Danay Saavedra</ext-link>, Center of Molecular Immunology, Cuba</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Miodrag Vrbic, <email>mvrbic@mts.rs</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>4</volume>
<elocation-id>1260053</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Vrbic and Milinkovic.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Vrbic and Milinkovic</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> The immune-inflammatory response is the basis of the pathophysiology of SARS-Cov-2 infection. In severe cases of COVID-19 uncontrolled systemic inflammatory response causes multiorgan dysfunction (MODS), as the most common immediate cause of death. Unfavorable outcome of the COVID-19 most often occurs in elderly patients. The aim of the study was to establish parameters with prognostic significance in severe cases of COVID-19 according to life years, laboratory markers of sepsis and MODS, as well as the number of peripheral CD4<sup>&#x2b;</sup> and CD8<sup>&#x2b;</sup>T lymphocytes in 20 consecutively selected critically ill patients.</p>
<p>
<bold>Results:</bold> Eleven subjects were male, 9 female, mean age 73.45 &#xb1; 11.59, among which the oldest patient was 94 and the youngest 43&#xa0;years. All the patients met the sepsis and MODS criteria. Increased age and low CD4<sup>&#x2b;</sup> and CD8<sup>&#x2b;</sup>T cell counts were identified as independent predictors of death. Only the two youngest patients (43 and 50&#xa0;years old) survived 28&#xa0;days, and they are the only ones with a CD4 lymphocyte count above 500 cells/mm<sup>3</sup>.</p>
<p>
<bold>Conclusion:</bold> Senescence of the immune system is mostly characterized by reduced regenerative capacity of adaptive immunity with diminished ability to respond to new antigens and a manifested proinflammatory phenotype. Additional reduction of protective capacity by further deterioration of T cell quantity and quality due to sepsis itself and mutual interaction of senescent T cells and vascular endothelial cells in the induction of cytokine storm represent two complementary vicious cycles in the development of sepsis-related multiorgan dysfunction.</p>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>MODS</kwd>
<kwd>senescence of adoptive immunity</kwd>
<kwd>sepsis</kwd>
<kwd>pathogenesis</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Aging and the Immune System</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Today, much is known about the clinical course and mortality of SARS-CoV-2 infection. Furthermore, current findings emphasize that the immune-inflammatory response plays a key role in its pathophysiology. Considering the wide distribution of angiotensin-converting enzyme 2 (ACE2), the functional receptor through which SARS-CoV-2 enters host cells, COVID-19 is a systemic disease. The first step in understanding of its pathogenesis is the abundant expression of ACE2 on respiratory tract epithelial cells and vascular endothelial cells (<xref ref-type="bibr" rid="B15">Pons et al., 2020</xref>). They represent an important component of innate immunity, causing a proinflammatory reaction, particularly violent in the presence of SARS-CoV-2 viremia, that is not detectable in mild and asymptomatic cases of COVID-19 (<xref ref-type="bibr" rid="B16">Richter et al., 2021</xref>). In severe cases of COVID-19, systemic inflammatory hyperactivation in the form of a cytokine storm causes sepsis-related MODS as the most common immediate cause of death (<xref ref-type="bibr" rid="B8">De Roquetaillade et al., 2021</xref>; <xref ref-type="bibr" rid="B10">Elezkurtaj et al., 2021</xref>).</p>
<p>Adverse disease outcomes are far more common in older patients (<xref ref-type="bibr" rid="B17">Santesmasses et al., 2020</xref>). The aging process itself is accompanied and guided by the aging of the immune system, primarily senescence of adoptive immunity, which is characterized by a reduction of its regenerative capacity, with a reduced protective capacity and a manifested pro-inflammatory phenotype. (<xref ref-type="bibr" rid="B1">Anna et al., 2019</xref>; <xref ref-type="bibr" rid="B6">Cunha et al., 2020</xref>). Dealing with these circumstances could contribute to a better understanding of the pathophysiological role of adaptive immunity, which is still not fully explained, in the development of severe forms of COVID-19.</p>
<p>In accordance with the given assumptions, the aim of the study was to establish the years of life, presence of sepsis and MODS, values of additional factors with confirmed prognostic significance and number of peripheral CD4<sup>&#x2b;</sup> and CD8<sup>&#x2b;</sup>T lymphocytes in critically ill patients with COVID-19.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<p>The study was conducted at the Clinic for Infectious Disease of University Clinical Center Nis, Serbia, from January to March 2022. Twenty patients were consecutively selected at the beginning of invasive mechanical ventilation, during hospitalization due to COVID-19.</p>
<p>Presence of mechanical ventilation, frequent need for sedation and use of vasoactive agents made impossible for us to use the clinical criteria (such as SOFA or qSOFA scoring) in the assessment of the presence and severity of sepsis and MODS. Therefore, various laboratory markers of sepsis and MODS were determined, including: interleukin 6 (IL-6), procalcitonin (PCT), C-reactive protein (CRP), white blood cell count (WBC), lymphocyte %, platelets count (PLT), glycemia, creatinine, lactate, international normalized ratio (INR), and PaO2/FiO2. Additionally, the values of lactate dehydrogenase (LDH), ferritin and D-dimer, with a confirmed prognostic significance for COVID-19, were determined. The numbers of peripheral CD4<sup>&#x2b;</sup> and CD8<sup>&#x2b;</sup>T lymphocytes were determined by flow cytometry (BD FACSCount&#x2122; Reagent Kit).</p>
<p>Analyzes were performed on blood samples taken on the same day, during the patients&#x27; stay in the intensive care unit. The results were presented as arithmetic means and standard deviations, with assessment of their association with the probability of death by univariate and multivariate Cox regression analysis and with Kaplan-Meier curve of 28 days survival.</p>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<p>All the patients met the sepsis and MODS criteria. Also, increased values of LDH, ferritin and D-dimer, as well as depletion of CD4 &#x2b; T and CD8 &#x2b; T lymphocytes were recorded (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Laboratory results presented as arithmetic means and standard deviations.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Analysis</th>
<th align="center">Values</th>
<th align="center">Reference ranges</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">IL-6</td>
<td align="center">304.89 &#xb1; 235.75&#xa0;pg/mL</td>
<td align="center">&#x3c;7&#xa0;pg/mL</td>
</tr>
<tr>
<td align="left">PCT</td>
<td align="center">27.66 &#xb1; 25.39&#xa0;ng/mL</td>
<td align="center">0.0&#x2013;0.05&#xa0;ng/mL</td>
</tr>
<tr>
<td align="left">CRP</td>
<td align="center">134.24 &#xb1; 115.56&#xa0;mg/L</td>
<td align="center">0.0&#x2013;5.0&#xa0;mg/L</td>
</tr>
<tr>
<td align="left">WBC count</td>
<td align="center">16.4 &#xb1; 9.4 &#xd7; 10<sup>9</sup>/L</td>
<td align="center">4.5 to 11.0 &#xd7; 10<sup>9</sup>/L</td>
</tr>
<tr>
<td align="left">Lymphocyte %</td>
<td align="center">5.3 &#xb1; 2.86%</td>
<td align="center">20%&#x2013;40%</td>
</tr>
<tr>
<td align="left">PLT</td>
<td align="center">118 &#xb1; 74 &#xd7; 10<sup>9</sup>/L</td>
<td align="center">120.0&#x2013;380.0 &#xd7; 10<sup>9</sup>/L</td>
</tr>
<tr>
<td align="left">Glycemia</td>
<td align="center">14.0 &#xb1; 5.3&#xa0;mmol/L</td>
<td align="center">3.9&#x2013;6.1&#xa0;mmol/L</td>
</tr>
<tr>
<td align="left">Creatinine</td>
<td align="right">240.2 &#xb1; 187.4&#xa0;&#x3bc;mol/L</td>
<td align="center">53.0&#x2013;115.0&#xa0;&#x3bc;mol/L</td>
</tr>
<tr>
<td align="left">Lactate</td>
<td align="center">5.0 &#xb1; 2.4&#xa0;mmol/L</td>
<td align="center">&#x3c;2.0&#xa0;mmol/L</td>
</tr>
<tr>
<td align="left">INR</td>
<td align="center">1.00 &#xb1; 0.16</td>
<td align="center">0.80&#x2013;1.20</td>
</tr>
<tr>
<td align="left">PaO2/FiO2</td>
<td align="center">115 &#xb1; 27</td>
<td align="center">&#x2265;400</td>
</tr>
<tr>
<td align="left">LDH</td>
<td align="center">553 &#xb1; 354 U/L</td>
<td align="center">220.0&#x2013;450.0 U/L</td>
</tr>
<tr>
<td align="left">Ferritin</td>
<td align="center">849.2 &#xb1; 389.3&#xa0;&#x3bc;g/L</td>
<td align="center">20.0&#x2013;250.0&#xa0;&#x3bc;g/L</td>
</tr>
<tr>
<td align="left">D-dimer</td>
<td align="center">5,939 &#xb1; 6,464&#xa0;ng/mL</td>
<td align="center">0.0&#x2013;250.0&#xa0;ng/mL</td>
</tr>
<tr>
<td align="left">CD4<sup>&#x2b;</sup> T cells</td>
<td align="center">172 &#xb1; 167 cells/mm<sup>3</sup>
</td>
<td align="center">500 to 1,500 cells/mm<sup>3</sup>
</td>
</tr>
<tr>
<td align="left">CD8<sup>&#x2b;</sup> T cells</td>
<td align="center">147 &#xb1; 191 cells/mm<sup>3</sup>
</td>
<td align="center">50 to 1,000 cells/mm<sup>3</sup>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>By univariate regression analysis, increased age and low CD4<sup>&#x2b;</sup>T and CD8<sup>&#x2b;</sup>T cells counts were identified as independent predictors of death. In the multivariate model of Cox regression analysis, containing the 3 given variables, only age retained statistical significance as the factor associated with mortality, probably as a cumulative expression of changes in the number of CD4<sup>&#x2b;</sup>T and CD8<sup>&#x2b;</sup>T lymphocyte cells (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Association with the probability of death by univariate and multivariate Cox regression analysis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="5" align="center">Univariate cox regression analysis</th>
</tr>
<tr>
<th rowspan="2" align="left">Factor</th>
<th rowspan="2" align="center">OR</th>
<th colspan="2" align="center">95% CI limits for OR</th>
<th rowspan="2" align="center">
<italic>p</italic>
</th>
</tr>
<tr>
<th align="center">LL</th>
<th align="center">UL</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<bold>Age</bold>
</td>
<td align="center">
<bold>1.108</bold>
</td>
<td align="center">
<bold>1.031</bold>
</td>
<td align="center">
<bold>1.190</bold>
</td>
<td align="center">
<bold>0.005</bold>
</td>
</tr>
<tr>
<td align="left">
<bold>Gender</bold>
</td>
<td align="center">0.971</td>
<td align="center">0.382</td>
<td align="center">2.472</td>
<td align="center">0.951</td>
</tr>
<tr>
<td align="left">
<bold>IL-6</bold>
</td>
<td align="center">0.996</td>
<td align="center">0.990</td>
<td align="center">1.003</td>
<td align="center">0.288</td>
</tr>
<tr>
<td align="left">
<bold>PCT</bold>
</td>
<td align="center">1.006</td>
<td align="center">0.990</td>
<td align="center">1.022</td>
<td align="center">0.471</td>
</tr>
<tr>
<td align="left">
<bold>CRP</bold>
</td>
<td align="center">1.003</td>
<td align="center">0.999</td>
<td align="center">1.007</td>
<td align="center">0.193</td>
</tr>
<tr>
<td align="left">
<bold>WBC</bold>
</td>
<td align="center">0.989</td>
<td align="center">0.930</td>
<td align="center">1.050</td>
<td align="center">0.710</td>
</tr>
<tr>
<td align="left">
<bold>Lymphocyte %</bold>
</td>
<td align="center">0.902</td>
<td align="center">0.755</td>
<td align="center">1.078</td>
<td align="center">0.256</td>
</tr>
<tr>
<td align="left">
<bold>PLT</bold>
</td>
<td align="center">0.996</td>
<td align="center">0.990</td>
<td align="center">1.003</td>
<td align="center">0.288</td>
</tr>
<tr>
<td align="left">
<bold>Glycemia</bold>
</td>
<td align="center">1.010</td>
<td align="center">0.906</td>
<td align="center">1.125</td>
<td align="center">0.860</td>
</tr>
<tr>
<td align="left">
<bold>Creatinine</bold>
</td>
<td align="center">1.001</td>
<td align="center">0.998</td>
<td align="center">1.005</td>
<td align="center">0.451</td>
</tr>
<tr>
<td align="left">
<bold>Lactate</bold>
</td>
<td align="center">1.049</td>
<td align="center">0.890</td>
<td align="center">1.236</td>
<td align="center">0.569</td>
</tr>
<tr>
<td align="left">
<bold>INR</bold>
</td>
<td align="center">0.914</td>
<td align="center">0.609</td>
<td align="center">1.371</td>
<td align="center">0.664</td>
</tr>
<tr>
<td align="left">
<bold>PaO2/FiO2</bold>
</td>
<td align="center">0.989</td>
<td align="center">0.966</td>
<td align="center">1.013</td>
<td align="center">0.354</td>
</tr>
<tr>
<td align="left">
<bold>LDH</bold>
</td>
<td align="center">1.000</td>
<td align="center">0.998</td>
<td align="center">1.001</td>
<td align="center">0.590</td>
</tr>
<tr>
<td align="left">
<bold>Ferritin</bold>
</td>
<td align="center">1.001</td>
<td align="center">1.000</td>
<td align="center">1.002</td>
<td align="center">0.149</td>
</tr>
<tr>
<td align="left">
<bold>D-dimer</bold>
</td>
<td align="center">1.000</td>
<td align="center">1.000</td>
<td align="center">1.000</td>
<td align="center">0.903</td>
</tr>
<tr>
<td align="left">
<bold>CD4<sup>&#x2b;</sup> T cells</bold>
</td>
<td align="center">
<bold>0.996</bold>
</td>
<td align="center">
<bold>0.992</bold>
</td>
<td align="center">
<bold>0.999</bold>
</td>
<td align="center">
<bold>0.022</bold>
</td>
</tr>
<tr>
<td align="left">
<bold>CD8<sup>&#x2b;</sup> T cells</bold>
</td>
<td align="center">
<bold>0.995</bold>
</td>
<td align="center">
<bold>0.990</bold>
</td>
<td align="center">
<bold>0.999</bold>
</td>
<td align="center">
<bold>0.028</bold>
</td>
</tr>
<tr>
<td colspan="5" align="center">Multivariate Cox regression analysis</td>
</tr>
<tr>
<td align="left">
<bold>Age</bold>
</td>
<td align="center">
<bold>1.119</bold>
</td>
<td align="center">
<bold>1.020</bold>
</td>
<td align="center">
<bold>1.227</bold>
</td>
<td align="center">
<bold>0.017</bold>
</td>
</tr>
<tr>
<td align="left">
<bold>CD4<sup>&#x2b;</sup> T cells</bold>
</td>
<td align="center">1.005</td>
<td align="center">0.996</td>
<td align="center">1.013</td>
<td align="center">0.292</td>
</tr>
<tr>
<td align="left">
<bold>CD8<sup>&#x2b;</sup> T cells</bold>
</td>
<td align="center">0.994</td>
<td align="center">0.986</td>
<td align="center">1.013</td>
<td align="center">0.165</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Only the two youngest patients (43 and 50&#xa0;years old) survived 28&#xa0;days, and these were the only ones with a CD4<sup>&#x2b;</sup>T lymphocyte count above 500 cells/mm<sup>3</sup> (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Kalpana-Meier curve of 28-day survival average survival time was 15.55 &#x2b; 1.75&#xa0;days.</p>
</caption>
<graphic xlink:href="fragi-04-1260053-g001.tif"/>
</fig>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Before the COVID-19 pandemic, in a cohort of patients with acute hypoxemic respiratory failure death was rarely due to refractory pulmonary dysfunction. In SARS-CoV-2 infection, pulmonary dysfunction is present in the vast majority of cases at the time of death, as the most conspicuous sign of MODS (<xref ref-type="bibr" rid="B13">Ketcham et al., 2021</xref>).</p>
<p>The development of severe forms and mortality from COVID 19 are associated with age-related changes in the immune response (<xref ref-type="bibr" rid="B2">Bartle et al., 2021</xref>). The pathogenetic substrate of MODS development is the cytokine storm primarily triggered by vascular endothelial damage (<xref ref-type="bibr" rid="B14">Otifi and Adiga, 2022</xref>). Further, as a conditional part of the acquired immunity, endothelial cells represent the interface between the innate and adaptive immune responses (<xref ref-type="bibr" rid="B18">Schleimer et al., 2007</xref>). They are important for the recruitment and activation of T-cells, which with aging exhibit increased production of proinflammatory cytokines (<xref ref-type="bibr" rid="B11">Fukushima et al., 2018</xref>; <xref ref-type="bibr" rid="B9">Degauque et al., 2021</xref>). At the same time, the senescent T cells may contribute to the immunopathological mechanism of additional endothelial damage, in the vicious circle of inflammatory hyperactivation (<xref ref-type="bibr" rid="B5">Covre et al., 2020</xref>; <xref ref-type="bibr" rid="B20">Zhang et al., 2021</xref>). Clinically, the significant role of adaptive immunity is indicated by the time required for its activation, 2&#xa0;weeks on average, considering that, in addition to the incubation period, serious forms of the disease usually develop 10&#xa0;days after the appearance of the first symptoms (<xref ref-type="bibr" rid="B3">Blair et al., 2021</xref>).</p>
<p>Another vicious circle present is a deterioration of the quantity and quality of T cells, that generally characterizes sepsis, which results in an additional reduction of the protective capacity of adaptive immunity, already weakened by immunosenescence (<xref ref-type="bibr" rid="B4">Cabrera-Perez et al., 2014</xref>; <xref ref-type="bibr" rid="B7">Danahy et al., 2016</xref>). From there, the presence of SARS-CoV-2 viremia and its duration were directly correlated with the degree of inflammation and mortality (<xref ref-type="bibr" rid="B12">Hagman et al., 2022</xref>), while depletion rate of peripheral CD8 &#x2b; T cells reflected the severity of the disease, and reduced CD4 &#x2b;T cell count was independently associated with increased in-hospital mortality in patients with COVID-19 (<xref ref-type="bibr" rid="B19">Wen et al., 2021</xref>).</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>The development of severe forms and mortality from COVID-19, as well as sepsis in general, is associated with an overwhelming life-threatening immune response associated with aging.</p>
<p>Driven primarily by changes of adaptive immunity, this process is mostly genetically programmed, which greatly reduces the possibility of therapeutic interventions.</p>
<p>From there, the most promising are therapeutic interventions which reduce the possibility of excessive immune activation, such as the administration of virustatic agents and neutralizing monoclonal antibodies early in the course of infection.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the ethical committee of the University Clinical Center of Ni&#x161; approved the study under number 4711/2. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>MV: Conceptualization, Data curation, Investigation, Methodology, Writing&#x2013;original draft. AM: Conceptualization, Supervision, Writing&#x2013;review and editing.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farzaneh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Candore</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davinelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gambino</surname>
<given-names>C. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>2247</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02247</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartleson</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Radenkovic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Covarrubias</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Furman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Winer</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Verdin</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2, COVID-19 and the ageing immune system</article-title>. <source>Nat. Aging</source> <volume>1</volume> (<issue>9</issue>), <fpage>769</fpage>&#x2013;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1038/s43587-021-00114-7</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blair</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Antar</surname>
<given-names>A. A. R.</given-names>
</name>
<name>
<surname>Keruly</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Bachu</surname>
<given-names>V. S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The clinical course of COVID-19 in the outpatient setting: A prospective cohort study</article-title>. <source>Open Forum Infect. Dis.</source> <volume>8</volume> (<issue>2</issue>), <fpage>ofab007</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofab007</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabrera-Perez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Condotta</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Badovinac</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Impact of sepsis on CD4 T cell immunity</article-title>. <source>J. Leukoc. Biol.</source> <volume>96</volume> (<issue>5</issue>), <fpage>767</fpage>&#x2013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.5MR0114-067R</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Covre</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>De Maeyer</surname>
<given-names>R. P. H.</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>D. C. O.</given-names>
</name>
<name>
<surname>Arne</surname>
<given-names>N. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The role of senescent T cells in immunopathology</article-title>. <source>Aging Cell</source> <volume>19</volume> (<issue>12</issue>), <fpage>e13272</fpage>. <pub-id pub-id-type="doi">10.1111/acel.13272</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Felix Perazzio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Azzi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cravedi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Riella</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>1748</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01748</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danahy</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Strother</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Badovinac</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Clinical and experimental sepsis impairs CD8 T-Cell-Mediated immunity</article-title>. <source>Crit. Rev. Immunol.</source> <volume>36</volume> (<issue>1</issue>), <fpage>57</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1615/CritRevImmunol.2016017098</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Roquetaillade</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bredin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lascarrou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soumagne</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cojocaru</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chousterman</surname>
<given-names>B. G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Timing and causes of death in severe COVID-19 patients</article-title>. <source>Crit. Care</source> <volume>25</volume> (<issue>1</issue>), <fpage>224</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-021-03639-w</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degauque</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Haziot</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brouard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mooney</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection</article-title>. <source>FASEB J.</source> <volume>35</volume> (<issue>5</issue>), <fpage>e21577</fpage>. <pub-id pub-id-type="doi">10.1096/fj.202100024R</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elezkurtaj</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Greuel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jana</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Bischoff</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kunze</surname>
<given-names>C. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Causes of death and comorbidities in hospitalized patients with COVID-19</article-title>. <source>Sci. Rep.</source> <volume>11</volume> (<issue>1</issue>), <fpage>4263</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-82862-5</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukushima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Minato</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The impact of senescence-associated T cells on immunosenescence and age-related disorders</article-title>. <source>Inflamm. Regen.</source> <volume>38</volume>, <fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/s41232-018-0082-9</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hedenstierna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rudling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gille-Johnson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hammas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grabbe</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: A cohort study</article-title>. <source>Diagn Microbiol. Infect. Dis.</source> <volume>102</volume> (<issue>3</issue>), <fpage>115595</fpage>. <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2021.115595</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ketcham</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Bolig</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Molling</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Sjoding</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Flanders</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>H. C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Causes and circumstances of death among patients hospitalized with COVID-19: A retrospective cohort study</article-title>. <source>Ann. Am. Thorac. Soc.</source> <volume>18</volume> (<issue>6</issue>), <fpage>1076</fpage>&#x2013;<lpage>1079</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.202011-1381RL</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otifi</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Adiga</surname>
<given-names>B. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Endothelial dysfunction in Covid-19 infection</article-title>. <source>Am. J. Med. Sci.</source> <volume>363</volume> (<issue>4</issue>), <fpage>281</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjms.2021.12.010</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pons</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arnaud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Loiselle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Azoulay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zafrani</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Immune consequences of endothelial cells&#x27; activation and dysfunction during sepsis</article-title>. <source>Crit. Care Clin.</source> <volume>36</volume> (<issue>2</issue>), <fpage>401</fpage>&#x2013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccc.2019.12.001</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richter</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Al Arashi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marx</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Aldabbagh</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Detectable SARS-CoV-2 RNAemia in critically ill patients, but not in mild and asymptomatic infections</article-title>. <source>Transfus. Med. Hemother</source> <volume>48</volume> (<issue>3</issue>), <fpage>154</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1159/000515841</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santesmasses</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pedro Castro</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zenin</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Shindyapina</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Gerashchenko</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>COVID&#x2010;19 is an emergent disease of aging</article-title>. <source>Aging Cell</source> <volume>19</volume> (<issue>10</issue>), <fpage>e13230</fpage>. <pub-id pub-id-type="doi">10.1111/acel.13230</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schleimer</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Epithelium: at the interface of innate and adaptive immune responses</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>120</volume> (<issue>6</issue>), <fpage>1279</fpage>&#x2013;<lpage>1284</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2007.08.046</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X. C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Clinical characteristics and predictive value of lower CD4&#x2b;T cell level in patients with moderate and severe COVID-19: A multicenter retrospective study</article-title>. <source>BMC Infect. Dis.</source> <volume>21</volume> (<issue>1</issue>), <fpage>57</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-020-05741-w</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Circulating senescent angiogenic T cells are linked with endothelial dysfunction and systemic inflammation in hypertension</article-title>. <source>J. Hypertens.</source> <volume>39</volume> (<issue>5</issue>), <fpage>970</fpage>&#x2013;<lpage>978</lpage>. <pub-id pub-id-type="doi">10.1097/HJH.0000000000002715</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>